



Received on 12 September, 2017; received in revised form, 21 March, 2018; accepted, 25 March, 2018; published 01 June, 2018

## EXPLORING THE BIOLOGICALLY ACTIVE METABOLITES OF *ISOCHRYSIS GALBANA* IN PHARMACEUTICAL INTEREST: AN OVERVIEW

N. Mishra and N. Mishra\*

Centre of Food Technology, University of Allahabad, Allahabad - 211002, Uttar Pradesh, India.

### Keywords:

Microalgae, *Isochrysis galbana*, Bioactive compounds, Biological activities, Pharmaceutical agent

### Correspondence to Author:

**Dr. Neetu Mishra**

Assistant Professor,  
Centre of Food Technology,  
University of Allahabad - 211002,  
Uttar Pradesh, India.

**E-mail:** neetum1976@gmail.com

**ABSTRACT:** Microalgae biomass has been recognized to have great potential as a source of novel bioactive compounds with industrial as well as health promoting applications in human, animal and aquatic lives. Microalgae have been gaining attention continuously due to its bioactive compounds. These bioactive compounds are primary and secondary metabolites produced by microalgae in order to adopt adverse environmental conditions. The simple growth requirement, higher mass productivity in short harvesting time making microalgae promising over other natural source of bioactive compounds. Several species of microalgae have undergone various screenings to identify and tap into these valuable resources, among them are the *Isochrysis galbana*, a brown microalgae belonging the class haptophyta. It is widely used as a feed for marine organism in aquaculture because of its high lipid content. Recently it is found *Isochrysis galbana* also exhibited the potential of being a source of high-value compounds with distinct biological activities including antitumor, antibacterial, antioxidant properties, anti-inflammatory and hypochloesteromic. These activities have a wide range of applications in various industries that have not been broadly explored and fully exploited. The aim of this review paper is to update previous researches on the biological activity of *Isochrysis galbana* and to explore it as a pharmaceutical agent.

**INTRODUCTION:** Nowadays, there is a huge interest among consumers and food industry on products that can promote good health, improve the state of wellbeing and decreases the risk of diseases<sup>1,2</sup>. Over the last few decades many microalgae has attracted the interest of researchers due to its high nutritional value and vast variety of novel metabolites that can be used in bioremediation<sup>3</sup>, biofuel<sup>4</sup>, biofertilizer<sup>5</sup>, human food<sup>6</sup>, animal feed<sup>6</sup>, and pharmaceutical industry<sup>7</sup>.

Extensive pharmaceutical and nutraceutical researches have being conducting globally for production of bioactive compounds from microalgae. Among these microalgae, *Isochrysis galbana* is one of the common marine microalgae used in mariculture to feed for bivalves & larva of fish, crustaceans, and mollusks<sup>8</sup>. Initially they have gained notice due to its high content of lipid that can be used in aquaculture and biofuel.

Recently, it has found *Isochrysis* also have balanced composition of several important bio-molecules, namely polysaccharides, fatty acid, carotenoids, vitamins, sterols which have the potential to improve the nutritional value of human foods, animal feed and have therapeutic potential against several diseases like cardiovascular disease cancer, diabetes, infectious diseases *etc.*<sup>9,10</sup>.

<b>QUICK RESPONSE CODE</b>	<b>DOI:</b> 10.13040/IJPSR.0975-8232.9(6).2162-74
	Article can be accessed online on: <a href="http://www.ijpsr.com">www.ijpsr.com</a>
DOI link: <a href="http://dx.doi.org/10.13040/IJPSR.0975-8232.9(6).2162-74">http://dx.doi.org/10.13040/IJPSR.0975-8232.9(6).2162-74</a>	

Nutraceutical and pharmaceutical scientists raised interest in *I. galbana* due to its simple growth requirement, ability to grow in extreme environmental condition, higher growth rate and productivity<sup>11</sup>. Isochrysis are golden brown marine photoautotrophic microalgae belonging to the class haptophyta that use light energy and inorganic nutrients (carbon dioxide, nitrogen, phosphorus, etc.) to develop and synthesize bio-compounds that have high aggregated nutritional and therapeutic values. The biochemical composition of microalgae is depends on growth phase and culture conditions. These are important factors that influence the metabolism of microorganisms, thus directing the synthesis of specific compounds of interest.

Therefore, culture conditions have to be optimized to maximize growth rate and production of valuable metabolites. *I. galbana* has been used as feed in aquaculture since long time<sup>10, 12</sup>. Although, limited studies found that explore its bioactive compounds and proves their therapeutic potential. This review aims to collate information from limited literature available on the great potential of biologically active metabolites of *Isochrysis galbana* for commercial uses. The aim of study is to review the main bioactive compounds in *I. galbana* and its therapeutic potential. Here we discuss few bioactive compounds- carotenoids, omega 3 fatty acid, sulfate polysaccharides and update previous researches on the biological activity of *Isochrysis galbana* to explore it as a pharmaceutical agent.

**Valuable Bioactive Compounds:** Bioactive compounds are heterogeneous group of essential and non-essential compounds commonly present in small concentrations in plants and food products. It has the potential to provide health benefits beyond the basic nutritional value of the product<sup>13</sup>. Recently microalgae have received attention due to its novel and structurally diverse bioactive compounds. They have unique ability to survive in adverse environmental condition and in order to adapt new environmental surroundings, they biosynthesize and accumulates different primary and secondary bioactive compounds that have potential pharmaceutical and therapeutic values<sup>14</sup>. These therapeutically effective compounds usually accumulated in biomass or in some cases released extracellular into the medium<sup>15</sup>. Most of the

valuable compounds produced by microalgae are secondary metabolites. These metabolites are nothing but organic compounds that do not accumulates or participate directly in growth or development, but appear under stress conditions<sup>16</sup>. Isochrysis characterized by fast growth rate, wide temperature and salinity tolerance and absence of toxins<sup>11</sup>. They contain many bioactive compounds, such as proteins, polysaccharides, lipids, carotenoids, vitamins, enzymes and other high-value compounds with pharmaceutical and nutritional importance that can be employed for commercial use<sup>9</sup>. This study reviews selected bioactive compounds-carotenoids, omega 3 FA, polysaccharides and its role in cardiovascular disease, neurodegenerative diseases and cancer.

**Carotenoids:** The main pigments of the *Isochrysis galbana* are the light harvesting pigments chlorophyll a, chlorophyll c, fucoxanthin and have diadinoxanthin in minor concentration<sup>16, 17, 18</sup>. Under light stress, diadinoxanthin can be converted into diatoxanthin that have higher ability to quenching of excessive light energy and protect it from light stress<sup>19, 20, 21</sup>. Fucoxanthin is a main carotenoid present in *Isochrysis galbana* exhibits potent antioxidant activities<sup>22, 23</sup>. After absorption in human body it is metabolized into fucoxanthinol, amarouciaxanthin A and halocynthiaxanthin<sup>24</sup>. Antioxidant activity (AO) of fucoxanthin is greater than other antioxidant compounds like beta carotene, alpha tocopherol and phenolic compounds.





FIG. 1: STRUCTURE OF FUCOXANTHIN

It has reported fucoxanthin has a strong radical scavenging activity as compare to other carotenoids such as zeaxanthin,  $\beta$ -carotene and lutein<sup>25</sup>. This attributed to the unique molecular structure of fucoxanthin, which have double allenic bonds at C-7' position with several conjugated double bond<sup>26</sup> as shown in **Fig. 1**. A number of studies have examined the metabolism, safety, and bioactivities of fucoxanthin, including its anti-cancer, anti-

obesity, antioxidant, anti-inflammatory, anti-diabetic, and anti-angiogenic activities<sup>27, 28</sup>.

**Omega 3 Polyunsaturated Fatty Acid:** Based on the position of first double bond in carbon chain, there are two types of polyunsaturated fatty acid (PUFA)-omega 3 fatty acid (n-3FA) and omega6 fatty acid (n-6FA). Most common type of n-6 FA are Linoleic acid (LA; C18:2), Arachidonic acid (AA; C20:4) and n-3 FA are  $\alpha$ -linolenic acid (ALA, 18:3), eicosapentaenoic (EPA; C20:5) and docosahexaenoic (DHA; C22:6) acids, structure were shown in **Fig. 2**. Both are essential fatty acids and are not synthesized by human due to the absence of enzyme required placing double bond at n-3 and n-6 position. LCPUFA especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) provide significant health benefits and needed to be supplied by diet.




**FIG. 2: STRUCTURE OF POLYUNSATURATED FATTY ACID**

Currently, Marine fatty fish are the key source of n-3 fatty acid (n-3FA) in human<sup>29</sup>. However, its undesirable taste, typical smell, cultural constraint, decline resources, increasing risk of contamination and prices, has created the demand for an alternative sources. Microalgae are the primary producer of EPA and DHA that are eventually accumulated to higher animal through food chain<sup>30</sup>. Vegetable sources are rich in LA, ALA but poor in EPA and DHA.

In the metabolic pathway of ALA, it converted into EPA & DHA however; this conversion of ALA into EPA and DHA in human is very low due to the deficiency of desaturase enzymes. Therefore, there is need to direct intake of EPA & DHA rich dietary

sources. Unlike human, in microalgae, n-3 and n-6 FA series are interconvertible as shown in **Fig. 3**.



**FIG. 3: BIOSYNTHETIC PATHWAY FOR THE POLYUNSATURATED FATTY ACID IN MICROALGAE**

EL- elongase enzyme DES- desaturase enzyme LA-Linoleic acid, ALA-alpha linolenic acid, SDA- stearidonic acid, GLA- gamma linolenic acid, DGLA- dihomo- $\gamma$  linolenic acid, ETA- eicosatetraenoic acid, AA-Arachidonic acid, EPA- eicosapentaenoic acid, DHA- docosapentaenoic acid, DHA- docosahexaenoic acid.


*Isochrysis galbana* is a marine microalga contain significant amount of LCPUFA in particular EPA and DHA. Although composition of lipid within cell differ with various culture conditions such as light intensity, culture medium composition, temperature. It has been acknowledged that n-3 FA particularly EPA & DHA play important role in many metabolic activities and have high therapeutic importance against cardiovascular disease (CVD), inflammatory disease, neuro-degenerative disease, cancer. There is currently a large demand for microalgae in the nutraceutical and pharmaceutical industry due to their sustainable productivity.

**TABLE 1: COMPARISON OF FATTY ACID COMPOSITION (% OF TOTAL FATTY ACID) OF *I. GALBANA* WITH COMMON VEGETABLE OILS<sup>31,32</sup>**

Fatty acid	<i>I galbana</i>	Sunflower	Safflower	Sesame	Rice Bran	Rapeseed
14:0	19.0	0.09	0.1	-	0.39	-
16:0	9.1	6.2	6.7	9.7	20.0	4.6
18:0	0.7	2.8	2.4	6.5	2.1	1.7
16:1	nd	0.12	0.08	0.11	0.19	0.21
18:1	10.4	28.0	11.5	41.5	42.7	63.3
18:2	6.5	62.2	79.0	40.9	33.1	19.6
18:3	9.6	0.16	0.15	0.21	0.45	1.2
SFA	29.1	9.4	9.3	9.4	22.5	6.3
MUFA	10.4	28.3	11.6	28.3	44.0	72.8
PUFA	34.5	62.4	79.1	62.4	33.6	20.9
n-3	28.0	0.2	0.2	0.2	0.5	1.2
n-6	10.0	62.2	79.0	62.2	33.1	19.6

**Table 1** illustrated comparison of fatty acid composition of *I. galbana* to the conventional vegetable oils and depicts that it could be possible dietary source of n-3FA in infant formula, animal feeds and human nutrition<sup>30</sup>.

**Polysaccharide:** Polysaccharide (PS) is polymeric carbohydrate structures that are formed of monosaccharide *via* different glycosidic bond. The carbohydrate content of *Isochrysis* represents around 13% of dry matter. Mono-sugar compositions of *Isochrysis* consist of 2.07% fucose, 2.50% rhamnose, 2.72% arabinose, 8.49% xylose, 15.7% mannose, 32.73% galactose and 35.79% glucose. Sun first isolated intracellular and extracellular polysaccharides from *Isochrysis galbana*. **Fig. 4** elicited it is a highly branched chain of  $\beta$ -type hetero polysaccharide with (1 $\rightarrow$ 3) (1 $\rightarrow$ 6) glucan<sup>33</sup>. Glucan contains linear chain of (1 $\rightarrow$ 6)-linked  $\beta$  glucopyranose (Glc) consist backbone of the structure. Every residue is substituted at position 3 by Glc, which in turn may be substituted at C-6 by a single Glc or by rather short (up to tetrasaccharide) oligosaccharide chains.<sup>34</sup> Polysaccharides have a wide array of biological activity like anticoagulant, immune-modulatory. These biological activities of polysaccharide depends on the ratio of 1 $\rightarrow$ 3 and 1 $\rightarrow$ 6 linkage (degree of branching) and chain length. Sun isolated three polysaccharides, IPSI-A, IPSI-B and IPSII from the *Isochrysis galbana* and demonstrated to have antioxidant activity<sup>35</sup>. They have wide range of biological activities and potential health benefits, making them interesting compounds for the application in therapeutics, and pharmaceuticals industry. It also has free radical scavenging ability and may reduce risk of chronic diseases like CVD, arthritis, cancer, neurodegenerative diseases.<sup>37, 38, 39</sup>



**FIG. 4: HIGHLY BRANCHED STRUCTURE OF THE  $\beta$ -GLUCAN FROM *I. GALBANA***<sup>34</sup>

### Biological Activity of *Isochrysis galbana*:

**Cardioprotective Activity:** Cardiovascular disease (CVD) is one of the leading causes of death worldwide<sup>40</sup>. CVD is a group of diseases that affect the heart, blood vessels and blood circulation include atherosclerosis, CHD, stroke, heart failure, thrombosis and peripheral arterial disease. Cardio protective activity of *I. galbana* is attributed to its antioxidant, anticoagulant and cholesterol lowering properties. It scavenges free radical, thereby prevent oxidation of low-density lipoproteins (LDL), which carry cholesterol into the blood stream, significant potential to cause atherosclerosis<sup>41</sup>. Nuno conducted an experiment on diabetic rat and found daily consumption of 50gm *Isochrysis galbana* for 8 weeks lower serum cholesterol and triglyceride accredited to its polysaccharide content<sup>42</sup>. Mechanisms involved in lowering cholesterol are not yet completely understood however; Oakenful proposed that it lowers serum cholesterol by increasing bile excretion and interfering with micelle formation and lipid absorption<sup>43</sup>.

It may also possess anticoagulant property, although there are only few studies on anticoagulant properties of microalgae<sup>44</sup>. The most recognized mechanism is that PS inhibits clot formation due to its heparin like activity. Pereira suggested the anti-coagulated properties of sulfated polysaccharides depends on its sulfated content particularly distribution/position of sulfate groups and configuration of polymer chain rather than amount of sulfur residue<sup>45</sup>. *Isochrysis galbana* has been acknowledged due to its high n-3 LCPUFA. Its regular consumption may reduce the risk of cardiac arrhythmias, myocardial infarction, thrombosis, and cardiac arrest<sup>46</sup>. n-3 has anti-arrhythmic activity based on the ability of EPA to incorporate into myocardial cell membranes<sup>47</sup>. Incorporation of EPA in the cell membrane potentially alters the eicosanoids production and ion channel function. It increases membrane fluidity in cardiac cells, thereby preventing atrial<sup>48, 49</sup>. Previous studies have demonstrated that EPA rich diet inhibits platelet aggregation, reduces blood viscosity, fibrinogen concentration, and increases plasmogen activator thus prevents CVD. However, further studies needed to explore the role of *Isochrysis galbana* in thrombosis, arrhythmia and other cardiac event.



**Antitumor Activity:** Cancer is a disease where cell continue to grow and divide. Multiple mechanism involve in cancer prevention includes, inhibition of excess cell growth, enhanced apoptosis, suppression of neoplastic transformation and antiangiogenicity. Free radical and progressive oxidative damage induces formation of cancer cell lines. Isochrysis have significant amount of antioxidant compound such as carotenoids (fucoxanthin), phenolic compounds, and  $\alpha$  tocopherol. Beneficial effect of fucoxanthin in prevention of cancer is well established<sup>50, 51</sup>. Several study had reported valuable effects of fucoxanthin in prevention of different type of carcinomas includes prostate and lung<sup>52</sup>, colon cancer<sup>53</sup>, lung cancer<sup>54, 55</sup>, urinary cancer, gastric cancer, breast cancer T cell leukemia<sup>56</sup>. Antitumor effect of fucoxanthin have been mediated through different mechanism includes apoptosis, arrest cell cycle, anti proliferation, anti angiogenesis<sup>57</sup>. Rodrigues and colleagues also found fucoxanthin was one of the strongest carotenoids only suppressed by astaxanthin for scavenging HOCl<sup>58</sup>.

The antioxidant activity of algal fucoxanthin is higher than  $\alpha$  tocopherol by effectively protecting from oxidative damage<sup>59</sup>. Antioxidant potential of *Isochrysis galbana* have been identified by Natrah et al may contribute in prevention of various type of cancer<sup>32</sup>. Usually antioxidant activities of carotenoids were assessed by DPPH, hydroxyl and Nitric oxide (NO) radical scavenging activity. Methanol extract of *Isochrysis galbana* have 34.18% DPPH radical scavenging properties, 67.35% hydroxyl radical scavenging properties, 37.33% NO scavenging properties<sup>61</sup>. Goiris et al., establish antioxidant activity of *Isochrysis galbana* is due to both carotenoid and phenolic content<sup>62</sup>. Although antioxidant activity of phenolic component of microalgae faltering. Li found no antioxidant activity of phenolic compound<sup>63</sup> whereas Jaime et al.,<sup>64</sup>, Geetha et al.,<sup>66</sup> Custódio et al.,<sup>66</sup> observed high antioxidant capacity of phenolic compound. This is further supported by Hajimahmoodi<sup>67</sup>, Custodio et al.,<sup>68</sup> demonstrated the antioxidant activity of microalgae is due to the presence of phenolic compounds.

Antitumor activity of *Isochrysis* species have been identified in many studies such as acetone extract of *I. galbana* T-ISO significantly reduced the

viability of human hepatic carcinoma Hepatic G2 cell<sup>68</sup>. Crude polysaccharide of *Isochrysis galbana* has immune-stimulating ability by the induction of IL-1 within murine macrophage<sup>69</sup>. Sadovskaya et al., confirmed the anti-tumor potential of PS extract of *Isochrysis sp.* as they inhibit the proliferation of U937 human leukemic monocyte lymphoma cells<sup>34</sup>. Sun et al isolated intracellular polysaccharide IPS-I, IPSII, IPSIII from *Isochrysis galbana* posses significant antioxidant properties<sup>33</sup>. Anti oxidative property of PS attributed due to its ability to prevent accumulation and activity of free radical and other reactive species<sup>38, 70</sup>.

Thereby, provide protection against oxidative and radical agent. Rocha de Souza<sup>71</sup> and Ye et al.,<sup>72</sup> found PS inhibits tumor cell proliferation in vitro and in mice. The exact mechanism of action is not known yet but it is suggested that it blocks the interaction of cancer cells with basement membrane and inhibit the adhesion of tumor cell to various substrate<sup>73</sup>. Role of n-3 fatty acids in prevention of cancers has not been fully established. It has found ratio of n3/n6 is a determining factor for the prevention of carcinogenesis<sup>74, 75</sup>. High n-6 and low n-3 FA produces inflammatory metabolites which increases proliferation of cells. *In vitro* studies found high AA induces pancreatic cancer whereas EPA suppresses<sup>76</sup>.

**Neuro- protective Activity:** Marine algae found to be a potent neuro protective agent and could be introduced for the preparation of novel functional ingredients in pharmaceuticals for the treatment and or prevention of neurodegenerative disease<sup>77</sup>. Excess production of free radical and reactive oxygen species (ROS) is the fundamental mechanism underlying human neurological disorder<sup>78</sup>. Overproduction of free radical leads oxidative stress and causes cellular damage that leads many neurological disorders to brain cells.

It is well stabilized that metal also generate highly toxic free radicals, resulting in oxidative damage responsible for the development of neurological disorders<sup>79</sup>. Radical scavenging and metal chelating activity is a valuable approach in treatment neurodegenerative diseases<sup>80, 81, 82</sup>. *I. galbana* have significant radical scavenging ability and have high ability to chelate Fe<sup>2+</sup> and Cu<sup>2+</sup><sup>60</sup>.

Antioxidant present in *Isochrysis* like fucoxanthin, tocopherol, and phenolic compound may prevent or reverse the age-related changes in the central nervous system. They exhibit antioxidant activity by scavenging free radical and other reactive species such as reactive oxygen species (ROS) & reactive nitrogen species (RNS) and chelating catalytic metals<sup>83</sup>. Fucoxanthin is a major carotenoid of *Isochrysis galbana* (1.85% DW) known for its antioxidant properties and neuroprotective activities<sup>84</sup>. Other theory advocated that n-3 FA plays a significant role in proper development of nervous system, cognitive development and memory related learning. It modulates electric signal transduction mechanism by affecting ion channel function and receptor system.

Composition of fatty acid in brain cell membrane increases neuro plasticity of nerve membrane, increases synaptic transmission, regulates production and transmission of neurotransmitters such as serotonin and dopamine<sup>85, 86</sup>. DHA is the major fatty acid of brain consists of 12-16% of total fatty acid in grey matters. It has been found in clinical trials that learning capacity and visual acuity increases with DHA<sup>87</sup>. Several studies documented the positive effect of DHA in neurological disorder<sup>88, 89, 90, 91</sup>.

Most possible mechanism is the ability of DHA to incorporate in brain cell membrane and thereby, increase membrane fluidity and ability to bind ligand which initiates transduction process<sup>92, 93, 94</sup>. Antalis *et al.*, found in their study that low blood DHA/EPA may lead behavioral disorders including attention-deficit/hyperactivity disorder (ADHD)<sup>95</sup>.

Previous researchers found that high consumption of DHA lowers the incidence of age-related cognitive decline, dementia, risk of Alzheimer's disease (AD) and epilepsy. Role of PS extract of *Isochrysis* in neurological disorder have not been reported. Although sulfated polysaccharide from the other brown algae exhibit neuroprotective effect by decreasing apoptosis in neuronal cells and acetyl cholinesterase (AChE) inhibitory activity<sup>96</sup>. Recently found PS have appreciable antioxidant capacity involves metals chelating and free radical scavenging properties. This further supports the neuro-protective activity of polysaccharides<sup>97, 98</sup>.

**Antimicrobial Activity:** Antimicrobial potential of microalgae has been recognized a long time ago. Microalgae extracts or their secondary products have inhibitory activity against many pathogens and cultured organism<sup>99, 100, 101, 102</sup>. Several compounds includes phenols, fatty acid, volatile halogenated hydrocarbons indoles, terpenes play important role in antimicrobial activity of microalgae. Antimicrobial activity of *Isochrysis* is attributed to its fatty acid content which vary with its different strain and cultural condition<sup>103</sup>. *Isochrysis galbana* produces and accumulates high content of lipid in stationary phase, when cells are not dividing. They release free fatty acid from lipid through enzymatic activity and discharge in media in late growth phase as a defensive mechanism against pathogenic bacteria, virus and other coexisting algae<sup>101, 104</sup>. These fatty acid and their derivatives have antibacterial activity against a wide range of gram negative and gram positive bacteria<sup>105</sup>. Antibacterial activity of fatty acid may be due to its ability to bring bacterial cell lyses<sup>106, 107, 108</sup>.

Duff noticed the ability of *Isochrysis galbana* to inhibit the growth of human pathogens such as *Streptococcus aureus* and *Streptococcus faecalis*, *proteus vulgaris*<sup>100</sup>. Srinivasakumar & Rajashekhar also found substantial activity of *Isochrysis galbana* against bacterial pathogens such as *E. coli* *Klebsiella pseudomoniae*, *Salmonella typhi*, however, not noticed any inhibitory activity against vibrio strains<sup>110</sup>. Recently, Ceres *et al.*, found *Isochrysis galbana* produces toxic substance that reduce the count of vibrio strains like *Vibrio alginolyticus*, *Vibrio campbellii*, and *Vibrio harvey* to the undetectable level within week<sup>111</sup>. Beside fatty acid, chlorophyll a derivatives such as pheophytin a and chlorophyllide found to have antibacterial activity<sup>112</sup>.

Polysaccharides from brown algae (Phaeophyceae) contain some antiviral properties<sup>113</sup>. It have been found to reduce the growth of enveloped viruses including members of the flavivirus, togavirus, arenavirus, rhabdovirus, orthopoxvirus, herpes virus families and HIV virus too. Endocellular extracts of *Isochrysis galbana* have growth inhibiting properties against virus *rhabdovirus* of viral haemorrhagic septicaemia (VHSV)<sup>108</sup>. Many microalgae releases toxic secondary metabolites inhibit the growth of either their own species or

other coexisting microalgae or both<sup>113</sup>. Yingying isolated growth inhibitor C<sub>22</sub>H<sub>38</sub>O<sub>7</sub> from death phage of *Isochrysis galbana* has inhibitory effect against the growth of other coexisting microalgae

like *Dunaliella salina*, *Platymonas elliptica*, *Chaetoceros muelleri* and *Phaeodactylum tricornutum*<sup>114</sup>.

**TABLE 2: IDENTIFIED BIOLOGICAL ACTIVITY OF ISOCHRYSIS GALBANA**

Component	Result	Inference	Reference
<i>Isochrysis galbana</i> in rat	Lowers blood glucose from 132.5mg/dl to 83.8mg/dl	Hypoglycemic potential	42
<i>Isochrysis galbana</i> in rat	Lowers blood lipid from 66mg/dl to 54mg/dl	Hypolipidemic potential	42
Hexane extract of <i>Isochrysis</i>	High DPPH, Hydroxyl, NO scavenging activity	Antioxidant activity	32
Methane extract of <i>Isochrysis</i>	High DPPH, Hydroxyl, NO scavenging activity	Antioxidant activity	61
Polysaccharide extract of <i>Isochrysis</i>	Inhibit of proliferation of U937 human leukemic monocyte lymphoma cell	Potential anti-tumour activity	34
Acetone extract of <i>Isochrysis</i>	Lower the viability of human carcinoma Hep G-2 cells	Anticancerous potential	68
Acetone extract of <i>Isochrysis</i>	Increase the ability of chelate Fe <sup>2+</sup> , have ability to inhibit AChE	Neuroprotective potential	68
Axenic <i>Isochrysis</i> culture	Effective to inhibit the growth of vibrio sp.	Antibacterial activity	110
Extract of <i>Isochrysis galbana</i>	Good antibacterial activity against pathogens <i>Klebisella pneumoniae</i> , <i>Proteus vulgaris</i> , <i>E. coli</i> , <i>Streptococcus aureus</i> , <i>Streptococcus facelis</i> , <i>Salmonella typhii</i>	Antibacterial activity	110, 115, 116
Cell free filtrate of <i>Isochrysis galbana</i>	Inhibit the growth of many coexisting microalga	Antialgal activity	114

Polysaccharides from brown algae (Phaeophyceae) contain some antiviral properties<sup>113</sup>. It have been found to reduce the growth of enveloped viruses including members of the flavivirus, togavirus, arenavirus, rhabdovirus, orthopoxvirus, herpes virus families and HIV virus too. Endocellular extracts of *Isochrysis galbana* have growth inhibiting properties against virus rhabdovirus of viral haemorrhagic septicaemia (VHSV)<sup>108</sup>. Many microalgae releases toxic secondary metabolites inhibit the growth of either their own species or other coexisting microalgae or both<sup>113</sup>. Yingying isolated growth inhibitor C<sub>22</sub>H<sub>38</sub>O<sub>7</sub> from death phage of *Isochrysis galbana* has inhibitory effect against the growth of other coexisting microalgae like *Dunaliella salina*, *Platymonas elliptica*, *Chaetoceros muelleri* and *Phaeodactylum tricornutum*<sup>114</sup>.

**Human Nutrition:** Microalgae have been used for food for thousands of years<sup>117</sup>. However, the commercial cultivation was started in the early 1960's in Japan with the culture of *Chlorella*<sup>118, 119, 120</sup>. Microalgae for human nutritional requirements are currently being merchandized in different forms

such as tablets, capsules, pastilles, liquids and nutritional supplements and are also incorporated into snacks, pastas, candy bars or chewing gum and in beverages<sup>121, 122</sup>. *I. galbana* has been used in aquaculture as animal feeds for century. Recently found it has high nutritional value with wide varieties of biologically active compounds. Nutritional composition of *I. galbana* studied by different researcher were shown in **Table 3**.

**TABLE 3: NUTRITIONAL COMPOSITION OF I. GALBANA**

Protein(%)	Carbohydrates(%)	Lipid(%)	References
40	26.8	14.5	Natrah <i>et al.</i> , <sup>32</sup>
27.1	34.32	10.54	Gorgonio <i>et al.</i> , <sup>125</sup>
29	12.9	23	Brown <sup>128</sup>
39.6	18	23.9	Fradigue <i>et al.</i> , <sup>130</sup>
38-40	8-17	18-24	Batista <i>et al.</i> , <sup>131</sup>
39.6	23.9	18	Guzman and Ascencio <sup>132</sup>

It has good amount of protein, soluble, insoluble carbohydrates and significant percentage of polyunsaturated fatty acid, which varies with growth phase and culture conditions. Under optimum condition, it contains 12% to 50.8% protein, 21.7% to 21.9% lipids, and 7.6% to 14.2% carbohydrates<sup>123, 124</sup>. *I. galbana* attracted the interest due to its high PUFA content.

The most common source of PUFA is fish and fish oil, although accumulated toxins, smell, poor oxidative stability limits its application in food additive. Declined fish resources, generates algal oil demands in market. *Isochrysis galbana* present the highest output of EPA (4.8% on dry basis) using vertical plate glass reactor<sup>126</sup> and have potential to use as source of n-3 FA in both nutraceuticals and animal feed industries.

Carbohydrate in microalgae is in form of starch, sugar and other polysaccharides. The carbohydrate content of *Isochrysis* comprises about 13% of dry matter and contains both soluble and insoluble carbohydrates with good digestibility<sup>127</sup>. It has been seen that its nutritional composition are comparable to the common vegetable food commodities **Table 4**<sup>125</sup> and they can be used in the diet of humans and animals as natural foods with health benefits. The high protein content and its amino acid pattern makes them non conventional protein source. **Table 4** elicited, the most abundant amino acids in *isochrysis* were glutamic acid and aspartic acid, whereas cysteine, methionine, tryptophan, and histidine were found in lower amounts (0.4% to 3.2%), and other amino acids were found in amounts between 3.2% to

13.5%<sup>128</sup>. Thus, their composition gives microalgae interesting qualities, which can be applied in human and animal nutrition. In addition, it contains biologically active compounds and possesses considerable antioxidant properties that could be applied in functional food and pharmaceutical industry<sup>60</sup>. However, prior to incorporation in food, drug and commercialization, algal material must be analyzed for the digestibility and presence of toxic compounds to prove their harmlessness. It have been found that its total digestibility is extremely high, which explains why there are no limitations to its use in foods and feeds<sup>127, 129</sup>.

In addition several toxicological assessments have not revealed any toxic impacts or abnormalities in experiments with test animals<sup>130</sup>. Fradique *et al.*, enhanced the nutritional value particularly EPA and DHA content of traditional pasta by incorporating *I. galbana*<sup>131</sup>. Nuno *et al.*, conducted a study on diabetic rat and found consumption of the microalga *I. galbana* promotes body weight loss in healthy animals and helped to maintain weight in diabetic animals and it lowers glucose and cholesterol values and raises lactic acid bacteria counts too<sup>42</sup>.

**TABLE 4: NUTRITIONAL COMPOSITION OF CONVENTIONAL FOOD WITH *I. GALBANA***<sup>32, 133</sup>

Composition	<i>I. galbana</i>	Milk	Soyabean	Egg	Fish	Meat
Protein (%)	47.9	26	37	49	55	43
Carbohydrates (%)	14.5	38	30	3	1	1
Lipid(%)	26.8	28	20	45	38	34
Amino acid (g/100g dry weight)						
Histidine	2.5	3.3	2.6	2.4	1.45	3.2
Arginine	8.7	3.3	7.4	6.2	3.82	6.6
Valine	6.0	5.7	5.3	7.2	2.77	5.3
Lysine	12.1	7.8	6.4	5.3	4.72	8.2
Isoleucine	4.9	4.3	5.3	6.6	2.66	5.1
leucine	10.5	9.2	7.7	8.8	4.48	7.8
Threonine	6.1	4.5	4.0	5.0	2.31	4.5
Phenylalanine	6.1	5.6	5.0	5.8	4.35	4.2
Methionine	1.42	1.3	1.3	3.2	2.31	2.4
Tryptophan	1.53	1.4	1.4	1.7	0.57	-

**CONCLUSION:** In conclusion *Isochrysis galbana* has high nutritional value with considerable amount of biologically active compounds like n-3 fatty acid, fucoxanthin, polysaccharides that have a potential to utilize in various industries includes aquaculture, pharmaceuticals and human nutrition. Initially, they got attention as aquaculture feed, however present review find *I. galbana* can be

alternative source of therapeutic and biological compounds such as essential amino acids, polysaccharides, monounsaturated and polyunsaturated fatty acids, and fucoxanthin. They have a potential to incorporate in various traditional food such as bakery, pasta, dairy and confectionary products without much intervention in sensory quality. Thus, it can be use for food enrichment,



nutritional supplements, and powered formulation and as tablet and capsule, which will help in reducing all health problems of human beings. Although, vast experimental analysis and well structural clinical trial needed to prove the role of different bioactive compounds of *Isochrysis galbana* in prevention of human diseases and also constant efforts in research and development in the field of marine research is needed.

**ACKNOWLEDGEMENT:** The authors are thankful to the Centre of Food Technology, University of Allahabad and UGC-PDF-WM Scheme.

**CONFLICTS OF INTEREST:** The authors have declared no conflicts of interest.

## REFERENCES:

1. Roberfroid M B: An European consensus of scientific concepts of functional foods. *Nutrition*. 2000; 16: 689-691.
2. Menrad K: Market and marketing of functional food in Europe. *Journal of Food Engineering*. 2003; 56: 181-188.
3. Batista AP, Ambrosano L, Graca S, Sousa C, Marques P A and Ribeiro B: Combining urban wastewater treatment with biohydrogen production-An integrated microalgae-based approach. *Bioresource Tech*. 2015; 184: 230-235.
4. Cai T, Park SY and Li Y: Nutrient recovery from wastewater streams by microalgae: Status and prospects. *Ren and Sustainable Energy Reviews*. 2013; 19: 360-369.
5. Song T, Martensson L, Eriksson T, Zheng W, Rasmussen, U: Biodiversity and seasonal variation of the cyanobacterial assemblage in a rice paddy field in Fujian, China. *The Federation of European Materials Societies Microbiology Ecology* 2005; 54: 131-140.
6. Chacon-Lee TL and Gonzalez-Marino GE: Microalgae for "Healthy" Foods - Possibilities and Challenges. *Comprehensive Reviews in Food Science and Food Safety*. 2010; 9: 655-675.
7. Torres FA, Passalacqua TG, Velásquez AM, de Souza RA, Colepicolo P and Graminha MA: New drugs with antiprotazoal activity from marine algae: a review. *Revista Brasileira de Farmacognosia*. 2014; 24(3): 265-76.
8. Pernet F, Tremblay R, Demers E and Roussy M: Variation of lipid class and fatty acid composition of *Chaetoceros muelleri* and *Isochrysis* sp. grown in a semi-continuous system. *Aquaculture*. 2003; 221(1):393-406.
9. Plaza M, Herrero M, Cifuentes A and Ibañez E: Innovative natural functional ingredients from microalgae. *Journal of Agr Food Chemistry*. 2009; 57: 7159-7170.
10. Guedes A., Amaro HM and Malcata FX: Microalgae as sources of high added-value compounds-a brief review of recent work. *Biotech Progress*. 2011; 27(3): 597-613.
11. Jeffrey SW, Brown MR, and Volkman JK: Haptophyte as feedstocks in mariculture. In J.C. Green and B.S.C. Leadbeater (eds.), *The Haptophyte Algae*, Clarendon Press, Oxford, 1994; 287-302.
12. Roy SS and Pal R: Microalgae in aquaculture: a review with special references to nutritional value and fish dietetics. In *Proceedings of the Zoological Society* 2015; 68(1): 1-8.
13. Gupta E, Purwar S, Sundaram S, Tripathi P and Rai G: Stevioside and Rebaudioside A–Predominant Ent-Kaurene Diterpene Glycosides of Therapeutic Potential—a Review. *Czech Journal of Food Sciences*. 2016; 34(4): 281-99.
14. Yamaguchi K: Recent advances in microalgal bioscience in Japan, with special reference to utilization of biomass and metabolites: a review. *Journal of Applied Phycology*. 1997; 8: 487-502.
15. Bhagavathy S, Sumathi P, and Jancy Sherene Bell I. Green algae *Chlorococcum humicola*-a new source of bioactive compounds with antimicrobial activity. *Asian Pacific Journal of Tropical Biomedicine*. 2011; 1(1): S1-S7.
16. Croteau R, Kutchan TM and Lewis NG: Natural products (secondary metabolites). *Biochemistry and Molecular Biology of Plants*. 2000; 24: 1250-1319.
17. Plaza M, Cifuentes A and Ibañez E: In the search of new functional food ingredients from algae. *Trends Food Science Technology*. 2008; 19: 31-39.
18. Liu CP and Lin LP. Ultrastructural study and lipid formation of *Isochrysis* sp. CCMP1324. *Botanical Bulletin of Academia Sinica*. 2001; 42: 207-214.
19. Jeffrey SW, Wright SW and Rao DS: *Algal Cultures, Analogues of Blooms and Applications*, 1995, New Hampshire
20. Lohr M and Wilhelm C. Algae displaying the diadinoxanthin cycle also possess the violaxanthin cycle. *Proceeding of National Academic Sciences USA*, 1999; 96: 8784-8789.
21. Telfer A, Pascal A and Gall A: *Carotenoids*, Birkhäuser, Basel. 2008; 4: 265-308.
22. Goss R and Jakob T: Regulation and function of xanthophyll cycle dependent photoprotection in algae. *Photosynthetic Research*. 2010; 106:103-122.
23. Sachindra, NM, Sato E, Maeda H, Hosokawa M, Niwano Y, Kohno M and Miyashita K: Radical scavenging and singlet oxygen quenching activity of marine carotenoid fucoxanthin and its metabolites. *Journal of Agriculture Food Chemistry*. 2007; 55: 8516-8522.
24. Sangeetha RK, Bhaskar N, Divakar S and Baskaran V: Bioavailability and metabolism of fucoxanthin in rats: structural characterization of metabolites by LC-MS (APCI). *Mol. Cellular Biochemistry*. 2010; 333: 299-310.
25. Nomura T, Kikuchi M, Kubodera A, Kawakami Y: Proton-donative antioxidant activity of fucoxanthin with 1,1-diphenyl-2-picrylhydrazyl (DPPH) *Biochem. Mol. Biol. Int*. 1997; 42: 361-370.
26. Yan X, Chuda Y, Suzuki M and Nagata T: Fucoxanthin as the major antioxidant in *Hizikia fusiformis*, a common edible seaweed. *Bioscience Biotechnology Biochemistry*. 1999; 63: 605-607.
27. Miyashita K, Nishikawa S, Beppu F, Tsukui T, Abe M, and Hosokawa M: The allenic carotenoid fucoxanthin, a novel marine netraceutical from brown seaweeds. *Journal of Science and Food Agriculture*. 2011; 91: 1166-74.
28. Peng J, Yuan JP, Wu CF and Wang JH: Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. *Mar Drugs*. 2011; 9: 1806-28.
29. Simopoulos AP: The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. *Exp. Biol. Med*. 2008; 233: 674-688.
30. Guedes AC, Amaro HM, Barbosa CR, Pereira RD, Malcata FX: Fatty Acid Composition of Several Wild Microalgae and Cyanobacteria, with a focus on Eicosapentaenoic, Docosahexaenoic and Linolenic Acids for Eventual Dietary Uses. *Food Research International*. 2011; 44: 2721-2729.

31. Orsavova J, Misurcova L, Ambrozova JV, Vicha R and Mlcek J: Fatty acids composition of vegetable oils and its contribution to dietary energy intake and dependence of cardiovascular mortality on dietary intake of fatty acids. *International Jou Mol Sci.* 2015; 16(6): 12871-90.
32. Patil V, Ka'llqvist T, Olsen E, Vogt G and Gislerød H R. Fatty acid composition of 12 microalgae for possible use in aquaculture feed. *Aqu International.* 2007; 15: 1-9.
33. Sun Y, Zhou B, Xu S, Li W, and Yan B: Separation and purification of intracellular and extracellular polysaccharides from *Isochrysis galbana* and their antimicrobial activity. *Food Sci.* 2012; 33(11): 137-141.
34. Sadovskayaa I, Anissa S., Sami S, Thierry G, Philippe Lencel a, Catherine M. Greenec, Sarah Duinc, Pavel S. Dmitrenok d, Alexander O. Chizhove, Alexander S. Shashkove, and Anatolii I. Usove: Chemical structure and biological activity of a highly branched (1→3,1→6)-d-glucan from *Isochrysis galbana*. *Carbohydrate Polymers.* 2014; 111:139-148.
35. Sun Y, Wang H, Guo G, Pu Y, and Yan B: The isolation and antioxidant activity of polysaccharides from the marine microalgae *Isochrysis galbana*. *Carbohydrate polymers.* 2014; 113:22-31.
36. Raposo MF, de Morais RM, Bernardo de Morais AM: Bioactivity and applications of sulphated polysaccharides from marine microalgae. *Mar Drugs.* 2013; 11(1): 233-52.
37. Herrero M, Jaime L, Martín-Alvarez PJ, Cifuentes A and Ibáñez E: Optimization of the extraction of antioxidants from *Dunaliella salina* microalga by pressurized liquids. *Journal of Agr. Food Chemistry.* 2006; 54:5597- 5603.
38. Li H, Cheng K, Wong C, Fan K, Chen F, and Jiang Y: Evaluation of antioxidant capacity and total phenolic content of different fractions of selected microalgae. *Food Chemistry.* 2007; 102:771-776.
39. Lee SH, Lee JB, Lee KW and Jeon YJ: Antioxidant properties of tidal pool microalgae, *Halochlorococcum porphyrae* and *Oltamanssiellopsis unicellularis* from Jeju Island, Korea. *Algae.* 2010; 25: 45-56.
40. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, Ahmed M, Aksut B, Alam T, Alam K, Alla F: Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. *Journal of the American College of Cardiology.* 2017 May 17.
41. Nakamura YK, Read MH, Elias JW: Oxidation of serum low density lipoprotein (LDL) and antioxidant status in young and elderly humans. *Archives Gerontology Geriatric.* 2006; 42 (3): 265-76.
42. Nuno K, Villarruel-Lopez A, Puebla-Perez AM, Romero-Velarde E, Puebla-Morad AG, and Ascencio F. Effects of the marine microalgae *Isochrysis galbana* and *Nannochloropsis oculata* in diabetic rats. *Journal of Functional Foods.* 2013; 5: 106-115.
43. Oakenfull D: Physicochemical properties of dietary fiber: Overview. *Food Science and Technology-New York-Marcel Dekker.* 2001; 17:195-206.
44. Ginzberg, A, Cohen, M, Sod-Moriah UA, Shany S, Rosenshtrauch A and Arad SM. Chickens fed with biomass of the red microalga *Porphyridium sp.* have reduced blood cholesterol levels and modified fatty acids composition in egg yolk. *Journal of Applied Phycology.* 2000; 12: 325-330
45. Pereira MS, Mulloy B and Mourao PAS: Structure and anticoagulant activity of sulfated fucans. Comparison between the regular, repetitive, and linear fucans from echinoderms with the more heterogeneous and branched polymers from brown algae. *Journal of Biological Chemistry.* 1999; 274: 7656-7667.
46. Horrocks LA and Yeo YK. Health benefits of docosahexaenoic acid (DHA). *Pharmacology Research.* 1999; 40: 211-225.
47. Gallai V, Sarchielli P, Trequattrini A, Franceschini M, Floridi A, Firenzi C, Alberti A, Di Benedetto D and Stragliotto E: Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. *Journal of Neuroimmunology.* 1995; 56:143-153.
48. Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK and Zhivotovsky LA, Feldman MW: Genetic structure of human populations. *Science.* 2002; 298:2381-2385.
49. Schwalfenberg G: Omega-3 fatty acids: their beneficial role in cardiovascular health. *Canadian Family Physician.* 2006; 52(6): 734-40.
50. Helmersson J, Arnlöv J, Larsson A and Basu S: Low dietary intake of  $\beta$ -carotene,  $\alpha$ -tocopherol and ascorbic acid is associated with increased inflammatory and oxidative stress status in a Swedish cohort. *British Journal of Nutrition.* 2009; 101: 1775-1782.
51. Kumar SR, Hosokawa M and Miyashita K: Fucoxanthin: A marine carotenoid exerting anti-cancer effects by affecting multiple mechanisms. *Marine Drugs* 2013; 11: 5130-5147.
52. Bhatt DL: Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention. *American Jou of Cardiology.* 2008; 101: 4-13.
53. Hosokawa M, Kudo M, Maeda H, Kohno H, Tanaka T and Miyashita K: Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPAR gamma ligand, troglitazone, on colon cancer cells. *Biochimica Biophysica Acta.* 2004; 1675: 113-119.
54. Kotake-Nara E, Asai A and Nagao A: Neoxanthin and fucoxanthin induce apoptosis in PC-3 human prostate cancer cells. *Cancer Letter.* 2005; 220:75-84.
55. Jaswir I, Noviendri D, Salleh HM, Taher M and Miyashita K: Isolation of fucoxanthin and fatty acids analysis of *Padina australis* and cytotoxic effect of fucoxanthin on human lung cancer (H1299) cell lines. *African Journal of Biotechnology.* 2011; 10:18855-18862.
56. Ishikawa C, Tafuku S, Kadokaru T, Sawada S, Tomita M, Okudaira T, Nakazato T, Toda T, Uchihara JN and Taira N: Anti-adult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. *International Jou of Cancer.* 2008; 123: 2702-2712.
57. Rengarajan T, Rajendran P, Nandakumar N, Balasubramanian MP and Nishigaki I: Cancer preventive efficacy of marine carotenoid fucoxanthin: cell cycle arrest and apoptosis. *Nutrients.* 2013; 5(12): 4978-4989.
58. Rodrigues E, Marintti LRB and Mercadante AZ: Scavenging capacity of marine carotenoids against reactive oxygen and nitrogen species in a membrane-mimicking system. *Marine Drugs.* 2012; 10: 1784-1798.
59. Heo SJ, Ko SC, Kang SM, Kang HS, Kim JP, Kim SH, Lee KW, Cho MG and Jeon YJ: Cytoprotective effect of fucoxanthin isolated from brown algae *Sargassum siliquastrum* against H<sub>2</sub>O<sub>2</sub>-induced cell damage. *European Food Research and Technology.* 2008; 228: 145-151.
60. Natrah FMI, Yusoff FM, Shariff M, Abas F and Mariana NS: Screening of Malaysian indigenous microalgae for antioxidant properties and nutritional value. *Journal of Applied Phycology* 2007, 19:711 718
61. Saranya C, Hemalatha A, Parthiban C and Anantharaman P: Evaluation of Antioxidant Properties, Total Phenolic and Carotenoid Content of *Chaetoceros calcitrans*, *Chlorella salina* and *Isochrysis galbana* *International*

- Journal of current Microbiology and Applied Sciences. 2014; 3(8): 365-377.
62. Goiris K, Muylaert K, Fraeye I, Foubert I, De Brabanter J, and De Cooman L: Antioxidant potential of microalgae in relation to their phenolic and carotenoid content. *Journal of Applied Phycology*. 2012; 804-6.
  63. Li H, Cheng K, Wong C, Fan K, Chen F, and Y Jiang: Evaluation of antioxidant capacity and total phenolic content of different fractions of selected microalgae. *Food Chemistry*. 2007; 102:771-776.
  64. Jaime L, Mendiola JA, Herrero M, Soler-Rivas C, Santoyo S, Señorans FJ, Cifuentes A and Ibáñez E: Separation and characterization of antioxidants from *Spirulina platensis* microalga combining pressurized liquid extraction, TLC, and HPLC-DAD. *Journal of Separation Science*, 2008; 28(16): 2111-2119.
  65. Geetha BV, Navasakthi R, Padmini E: Investigation of antioxidant capacity and phytochemical composition of Sun Chlorella - an *in vitro* study. *Journal of Aquaculture Research Development*. 2010; 1:104.
  66. Custódio L, Escapa AL, Fernandes E, Fajardo A, Aligüé R, Alberício F, Neng N, Nogueira JMF and Romano A: Phytochemical profile, antioxidant and cytotoxic activities of the carob tree (*Ceratonia siliqua* L.) germ flour extracts. *Plant foods for human nut*. 2011; 66(1): 78-84.
  67. Hajimahmoodi M, Faramarzi MA, Mohammadi N, Soltani N, Oveisi MR, and N Nafissi-Varcheh: Evaluation of antioxidant properties and total phenolic contents of some strains of microalgae. *Jou App Phy*. 2010; 22: 43-50.
  68. Custódio L, Soares F, Pereira H, Barreira L, Vizetto-Duarte C, Rodrigues MJ, Rauter AP, Alberício F and João Varela: Fatty acid composition and biological activities of *Isochrysis galbana* T-ISO, *Tetraselmis sp.* and *Scenedesmus sp.*: possible application in the pharmaceutical and functional food industries. *Journal of Applied Phycology*. 2014; 26(1):151-161
  69. Yu CC, Chen HW, Chen MJ, Chang YC, Chien SC, Kuo YH, Yang FL, Wu SH, Chen J, Yu HH and Chao LK: Chemical composition and bioactivities of the marine alga *I. galbana* from Taiwan. *Natural product communications*, 2010; 5(12):1941-1944.
  70. Li L-Y, Li L-Q P, Guo C-H: Evaluation of *in vitro* antioxidant and antibacterial activities of *Laminaria japonica* polysaccharides. *Journal of Medicinal Plants research*. 2010; 4(21): 2194 - 2198.
  71. Rocha de Souza MC, Marques CT, Dore CMG, Ferreira da Silva FR, Rocha HAO, and Leite EL: Antioxidant activities of sulphated polysaccharides from brown and red seaweeds. *Jou of Applied Phycology*, 2007; 19: 153-160.
  72. Ye H, Wang K, Zhou C, Liu J, and Zeng X: Purification, antitumor and antioxidant activities *in vitro* of polysaccharides from the brown seaweed *Sargassum pallidum*. *Food Chemistry*. 2008; 111: 428-432.
  73. Wijesekara I, Kim SJ, Pangestuti R: Review- Biological activities and potential health benefits of sulfated polysaccharides derived from marine algae. *Carbohydrate Polymers*. 2011; 84: 14-21.
  74. Ge YL, Chen Z, Kang ZB, Cluette-Brown J, Laposata M and Kang JX: Effects of adenoviral transfer of *Caenorhabditis elegans* n-3 fatty acid desaturase on the lipid profile and growth of human breast cancer cells. *Anticancer Research*. 2002; 22:537-544.
  75. Kang ZB, Ge Y, Chen Z, Brown J, Laposata M, Leaf A, Kang JX: Adenoviral transfer of *Caenorhabditis elegans* n-3 fatty acid desaturase optimizes fatty acid composition in mammalian heart cells. *Proceedings of the National Academy of Sciences*. 2001; 98: 4050-4054.
  76. Funahashi H, Satake M, Hasan S, Sawai H, Newman RA, Reber HA, Hines OJ and Eibl G: Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. *Pancreas*. 2008; 36: 353-362.
  77. Pangestuti R and Kim SK: Neuroprotective effects of marine algae. *Marine drugs*. 2011; 9(5): 803-18.
  78. Delanty N and Dichter MA: Antioxidant therapy in neurologic disease. *Archives Neurology*. 2000; 57(9): 1265-70.
  79. Gaeta A and Hider RC: The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. *Bri Jou of pharmacology*. 2005; 146(8): 1041-59.
  80. Nunomura A, Castellani RJ and Zhu X: Involvement of oxidative stress in Alzheimer disease. *Journal of Neuropathology Exp. Neurology*. 2006; 65(7): 631-41.
  81. Onyango IG, Khan SM: Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. *Current Alzheimer Research*. 2006; 3(4):339-49.
  82. Sinclair AJ, Bayer AJ and Johnston J: Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. *International Journal of Geriatric Psychiatry*. 1998; 13(12): 840-5.
  83. Büyükköroğlu ME, Gülçin I and Oktay M: *In vitro* antioxidant properties of dantrolene sodium. *Pharmacological Research*. 2001; 44: 491-495.
  84. Kim SM, Kang, SW, Kwon ON, Chung D and Pan CH: Fucoxanthin as a major carotenoid in *Isochrysis aff. galbana*: Characterization of extraction for commercial application. *Journal of the Korean Society for Applied Biological Chemistry*. 2012; 55(4): 477-483.
  85. Fenton WS, Dickerson F and Boronow J: A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. *American Journal of Psychiatry* 2001; 158: 2071-2074.
  86. Dubois J, Hertz-Pannier L, Dehaene-Lambertz G, Cointepas Y and Le Bihan D: Assessment of the early organization and maturation of infants' cerebral white matter fiber bundles: a feasibility study using quantitative diffusion tensor imaging and tractography. *Neuroimage*. 2006; 30(4): 1121-1132.
  87. Birch EE, Stager DR, Sr, Stager DR, Jr and Berry PM: Risk factors for esotropic amblyopia. *Investigative Ophthalmology & Visual Science*. 2007; 48:1108.
  88. Bromfield EB, Dworetzky S, Hurwitz Z, Eluri L, Lane S, Replansky, and Mostofsky D: A randomized trial of polyunsaturated fatty acids for refractory epilepsy. *Epilepsy and Behavior*. 2008; 12(1):187-190.
  89. DeGiorgio CMP, Miller S, Meymandi and Gornbein JA: N-3 fatty acids (fish oil) for epilepsy, cardiac risk factors, and risk of sudep: Clues from a pilot, double-blind, exploratory study. *Epilepsy and Behavior*, 2008; 13(4): 681-684.
  90. Garbagnati FG, Cairella A, De Martino, Multari M, Scognamiglio U, Venturiero V and Paolucci S: Is antioxidant and n-3 supplementation able to improve functional status in poststroke patients? Results from the Nutristroke Trial. *Cerebrovascular Diseases*, 2009; 27(4): 375-383.
  91. Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA and Anderson CS: Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: A randomized, controlled trial. *Stroke*. 2009; 40(11): 3485-3492.
  92. Stubbs C and Smith A: The modification of mammalian membrane polyunsaturated fatty acid composition in



- relation to membrane fluidity and function. *Biochimica Biophysica Acta*. 1984; 779:89-137.
93. Wood JN: Essential fatty acids and their metabolites in signal transduction. *Biochemical Society Transactions*. 1990; 18: 785-786.
  94. Mitchell DC, Niu SL, Litman BJ: DHA-rich phospholipids optimize G-protein coupled signaling. *Journal of Pediatrics*. 2003; 143: S80-S86.
  95. Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K, Burgess JR: Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. *Prostaglandins Leukotriens Essential Fatty Acids*. 2006; 75: 299-308.
  96. Pangestuti and Se-Kwon Kim Review Neuro-protective Effects of Marine Algae. *Mar Drugs* 2011. 9(5): 803-818.
  97. Wang J, Sun BG, Cao YP, Tian YA and Li XH: Optimisation of ultrasound-assisted extraction of phenolic compounds from wheat bran. *Food Chemistry*. 2008; 106: 804-810.
  98. Arivuselvan N, Radhiga M, Anantharaman P: *In vitro* antioxidant and anticoagulant activities of sulphated polysaccharides from brown seaweed (*Turbinaria ornata*). *Asian Journal of Pharma Biological Research*. 2011; 1: 232-239.
  99. Duff DC, Bruce DL, Antia NJ: The antibacterial activity of marine planktonic algae. *Canada Journal of Microbiology*. 1966; 12:878-884.
  100. Desbois AP and Smith VJ: Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. *Applied microbiology and biotechnology*. 2010; 85(6):1629-42.
  101. Shin SY, Bajpai VK, Kim HK and Kang SC: Antibacterial activity of bioconverted eicosapentanoic (EPA) and docosahexaenoic acid (DHA) against food borne pathogenic bacteria. *International Journal of Food Microbiology*. 2007; 113: 233-236.
  102. Molina-Grima E, Sanchez-Perez JA, Garcia-Camacho F, Fernandez-Sevilla JM and Acien-Fernandez FG: Effect of growth rate on the eicosapentanoic acid and docosahexaenoic acid content of *Isochrysis galbana* in chemostat culture. *Applied Microbiology Biotech*. 1994; 41: 23-27.
  103. Zhu CJ, Lee YK and Chao TM: Effects of temperature and growth phase on lipid and biochemical composition of *Isochrysis galbana* TK1. *Journal of Applied Phycology*. 1997; 9:451-457
  104. Fábregas J, García D, Fernández AM, Rocha AL, Gómez P, Escribano JM and Otero A, Coll JM: *In vitro* inhibition of replication of septicemia virus (VHS) and African swine fever virus (ASFV) by extracts from marine microalgae. *Antiviral Research*. 1999; 44:67-73.
  105. Srinivasakumar KP and Rajashekhar M: *In vitro* studies on bactericidal activity and sensitivity pattern of isolated marine microalgae against selective human bacterial pathogens. *Ind Jou of Sci Tech*. 2009; 2: 16-23.
  106. Ceres A and Molina-Cárdenas M, del Pilar Sánchez-Saavedra, Marcial L, Lizárraga - Partida. Inhibition of pathogenic Vibrio by the microalgae *Isochrysis galbana*. 2014; 26(6): 2347-2355.
  107. Bruce DL, Duff DCB and Antia NJ: The identification of two antibacterial products of the marine planktonic alga *I. galbana*. *Jou Gen Micro*. 1967; 48: 293-298.
  108. Vo TS and Kim SK: Potential anti-HIV agents from marine resources: an overview. *Marine Drugs*. 2010; 8(12): 2871-2892.
  109. Hellebust JA. Extracellular products: Algal Physiology and Biochemistry. (Stewart WDP edn), University of California Press, Oxford. 1974; 838-863.
  110. Yingying S, Changhai W and Jing C: Growth inhibition of eight species of microalgae by growth inhibitor from the culture of *Isochrysis galbana* and its isolation and identification. *Journal of Applied Phycology*. 2008; 20: 315-321.
  111. Kumaran J, Mathan S, and Prakash S: Preliminary studies on antimicrobial activity of selected marine micro algal extracts against human pathogens. *International Journal of Medical Sciences (India)*. 2010; 2(2):159-65.
  112. Rubavathi S and Ramya M: *In vitro* Assessment of Antimicrobial and Antioxidant Activity of Bioactive Compounds from Marine Algae. *International Journal of Current Microbiology and Applied Sciences*. 2016; 5(7): 253-66.
  113. Jensen GS, Ginsberg DI, and Drapeau MS: Bluegreen algae as an immuno-enhancer and biomodulator. *Journal of. American Nutraceutical Association*. 2001; 3: 24-30.
  114. Borowitzka MA: Commercial production of microalgae: ponds, tanks, tubes and fermenters. *Journal of Biotechnology*. 1999; 70: 313- 321.
  115. Muller-Feuga A: Microalgues marines. Les enjeux de la recherche. Institut Français de Recherche pour l'Exploitation de la Mer, Plouzané. 1996
  116. Iwamoto H: Industrial production of microalgal cell-mass and secondary products - major industrial species - *Chlorella*, p. 255-263. In Richmond, A. (ed.), *Handbook of microalgal culture*. Blackwell, Oxford 2004.
  117. Spolare P, Joannis-Cassan C, Duran E and Isambert A: Commercial Applications of Microalgae. *Journal of Bioscience and Bioengineering*. 2006; 101(2): 87-96.
  118. Gouveia L, Batista AP, Raymundo A and Bandarra NM: *Spirulina maxima* and *Diacronema vlkianum* microalgae in vegetable gelled desserts. *Nutrition and Food Science*. 2008; 38: 492-501.
  119. Fidalgo JP, Cid A, Torres E, Sukenik A and C. Herrero: Effects of nitrogen source and growth phase on proximate biochemical composition, lipids classes and fatty acid profile of the marine microalga *Isochrysis galbana*. *Aquaculture*. 1998; 166: 105-116.
  120. Renaud SM, Thinh LV, Lambrinidis G and Parry DL: Effect of temperature on growth, chemical composition and fatty acid composition of tropical Australian microalgae grown in batch cultures. *Aquaculture*. 2002; 211(1): 195-214.
  121. da Silva Gorgônio CM, Aranda DA and Couri S: Morphological and chemical aspects of *Chlorella pyrenoidosa*, *Dunaliella tertiolecta*, *Isochrysis galbana* and *Tetraselmis gracilis* microalgae. *Natural Science*. 2013; 5(7): 783.
  122. Zhang CW, Richmond A: Sustainable, high-yielding outdoor mass cultures of *Chaetoceros muelleri* var. subsalsum and *Isochrysis galbana* in vertical plate reactors. *Marine Biotechnology*. 2003; 5: 302-310.
  123. Becker W: Microalgae for Aquaculture the Nutritional Value of Microalgae for Aquaculture. In Richmond, A. (eds.) *Handbook of Microalgal Culture Biotechnology and Applied Phycology*. Oxford 2004; 380-391.
  124. Brown MR, Jeffrey SW, Volkman JK, Dunstan GA: Nutritional property of microalgae for mariculture. *Aquaculture*. 1997; 151: 315-331.
  125. Soletto D, Binaghi L, Lodi A, Carvalho JCM, Converti A: Batch and fedbatch cultivations of *Spirulina platensis* using ammonium sulphate and urea as nitrogen sources. *Aquaculture*. 2005; 243: 217-224
  126. Fradique M, Batista AP, Nunes MC, Gouveia L, Bandarra NM, Raymundo A: *Isochrysis galbana* and *Diacronema vlkianum* biomass incorporation in pasta products as



- PUFA's source. LWT-Food Science and Technology. 2013; 50(1): 312-9.
127. Batista AP, Gouveia L, Bandarra Narcisa M, Franco JM and Raymundo A: Comparison of microalgal biomass profiles as novel functional ingredient for food products. Algal Research. 2013; 2: 164-173.
128. Guzmán-Murillo MA and Ascencio F: Anti-adhesive activity of sulphated exopolysaccharides of microalgae on attachment of the red sore disease-associated bacteria and *Helicobacter pylori* to tissue culture cells. Letters in Applied Mic. 2000; 30: 473-478.
129. Microalgae nutritional composition retried from <http://www.algae4feed.org>, 2010, International Journal Molecular Science. 2015; 16(6): 12871-12890.
130. Naviner M, Bergé JP, Durand P and Le Bris H: Antibacterial activity of the marine diatom *Skeletonema costatum* against aquacultural pathogens. Aquaculture. 1999; 174:15-24.
131. Sánchez-Saavedra MP, Licea-Navarro A and Bernáldez-Sarabia J: Evaluation of the antibacterial activity of different species of phytoplankton. Review Biology Marine Oceanography. 2010; 45:531-536.
132. González-Davis O, Ponce-Rivas E, Sánchez-Saavedra MP, Muñoz-Márquez E and Gerwick W: Bioprospection of microalgae and cyanobacteria as biocontrol agents against *V. campbellii* and their use in white shrimp *Litopenaeus vannamei* culture. Journal of World Aquaculture Society. 2012; 43: 387-399.
133. Pesando D: Antibacterial and antifungal activities of marine algae. In: Akatsuka I (ed) Introduction to applied phycology. SPB Academic Publishing, The Hague, 1999; 3-26.

**How to cite this article:**

Mishra N. and Mishra N.: Exploring the biologically active metabolites of *Isochrysis galbana* in pharmaceutical Interest: An Overview. Int J Pharm Sci Res 2018; 9(6): 2162-74. doi: 10.13040/IJPSR.0975-8232.9(6).2162-74.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **ANDROID OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)